Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

A. J. Jakubowiak, D. S. Siegel, T. Martin, M. Wang, R. Vij, S. Lonial, S. Trudel, V. Kukreti, N. Bahlis, M. Alsina, A. Chanan-Khan, F. Buadi, F. J. Reu, G. Somlo, J. Zonder, K. Song, A. K. Stewart, E. Stadtmauer, B. L. Harrison, A. F. WongR. Z. Orlowski, S. Jagannath

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Fingerprint Dive into the research topics of 'Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study'. Together they form a unique fingerprint.

Medicine & Life Sciences